What is the latest GLAND stock price?
The latest stored price for GLAND is Rs 2,819.30 as of 2026-08-21.
gimli
GLAND stock AI analysis
GLAND Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
GLAND PHARMA LIMITED is a mid-cap stock in Healthcare. This Gimli page shows the latest available GLAND price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹2,819.30
1W return
-5.08%
1M return
+13.57%
3M return
+20.95%
6M return
+54.76%
1Y return
+44.97%
Market cap
₹46,449.77 cr
PE
39.49
PB
4.48
ROE
+12.06%
ROCE
+8.77%
RSI
62.23
Turnover
₹68.97 cr
Why it can matter in screens
- Momentum: GLAND is above 50DMA, above 200DMA; RSI is 62.23.
- Returns: 1D -0.02%, 1W -5.08%, 1M +13.57%, 3M +20.95%, 1Y +44.97%.
- Trend levels: 52W high ₹3,039.80, 52W low ₹2,167.80, off high -7.25%.
- Liquidity: latest turnover is ₹68.97 cr; volume vs 20D is +0.27%.
- Valuation/profitability: PE 39.49, PB 4.48, ROE +12.06%, ROCE +8.77%.
- Growth: 3Y sales CAGR +21.42%, 3Y profit CAGR +9.56%.
Quick Answers
Is GLAND above its 50DMA and 200DMA?
GLAND is above 50DMA, above 200DMA. The latest 50DMA is 2,512.30 and the latest 200DMA is 1,994.24.
What are GLAND PE, ROE and ROCE?
GLAND has PE 39.49, ROE +12.06%, and ROCE +8.77% in Gimli's latest available snapshot.
How has GLAND performed recently?
GLAND has returned +13.57% over 1 month, +20.95% over 3 months, and +44.97% over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-06-30 | 1,345.46 cr | 532.33 cr | 364.39 cr | 22.10 |
| 2026-03-31 | 1,742.79 cr | 624.49 cr | 366.68 cr | 22.26 |
| 2025-12-31 | 1,695.36 cr | 473.70 cr | 261.48 cr | 15.87 |
| 2025-09-30 | 1,571.00 cr | 398.05 cr | 183.68 cr | 11.15 |
| 2025-06-30 | 1,505.62 cr | 425.29 cr | 215.48 cr | 13.08 |
| 2025-03-31 | 1,424.91 cr | 391.54 cr | 186.54 cr | 11.32 |
| 2024-12-31 | 1,384.05 cr | 418.45 cr | 204.69 cr | 12.42 |
| 2024-09-30 | 1,405.83 cr | 356.72 cr | 163.53 cr | 9.93 |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 6,430.65 cr | 1,921.53 cr | 1,027.32 cr | 62.35 |
| 2025-03-31 | 5,616.50 cr | 1,482.53 cr | 698.53 cr | 42.40 |
| 2024-03-31 | 5,641.73 cr | 1,498.90 cr | 772.46 cr | 46.90 |
| 2023-03-31 | 3,591.86 cr | 1,207.61 cr | 781.04 cr | 47.44 |
| 2022-03-31 | 4,624.65 cr | 1,732.25 cr | 1,212.16 cr | 73.67 |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 12,510.85 cr | 3,359.11 cr | 283.59 cr | 10,357.95 cr |
| 2025-03-31 | 11,224.92 cr | 2,556.19 cr | 313.73 cr | 9,150.74 cr |
| 2024-03-31 | 10,661.25 cr | 357.09 cr | 372.17 cr | 8,723.84 cr |
| 2023-03-31 | 8,777.53 cr | 1,908.89 cr | 4.45 cr | 7,958.72 cr |
| 2022-03-31 | 7,833.62 cr | 294.82 cr | 4.74 cr | 7,157.62 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | 1,031.39 cr | 536.96 cr | n/a |
| 2025-03-31 | 914.73 cr | 520.56 cr | n/a |
| 2024-03-31 | 996.80 cr | 598.54 cr | n/a |
| 2023-03-31 | 363.97 cr | 140.85 cr | n/a |
| 2022-03-31 | 790.77 cr | 268.65 cr | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-06-30 | +51.77% | +8.74% | +30.44% | +28.23% | +9.05% | +0.00% |
| 2026-03-31 | +51.83% | +7.30% | +33.35% | +31.78% | +7.52% | +0.00% |
| 2025-12-31 | +51.83% | +7.58% | +32.98% | +31.42% | +7.61% | +0.00% |
| 2025-09-30 | +51.83% | +7.91% | +32.64% | +30.19% | +7.63% | +0.00% |
| 2025-06-30 | +51.83% | +7.39% | +32.85% | +30.67% | +7.93% | +0.00% |
| 2025-03-31 | +51.83% | +6.90% | +33.27% | +31.16% | +7.99% | +0.00% |
| 2024-12-31 | +51.83% | +5.04% | +34.80% | +32.37% | +8.33% | +0.00% |
| 2024-09-30 | +51.83% | +4.47% | +35.37% | +32.83% | +8.32% | +0.00% |
| 2024-06-30 | +51.83% | +6.88% | +32.83% | +30.53% | +8.45% | +0.00% |
| 2024-03-31 | +57.86% | +3.59% | +25.23% | +23.01% | +13.32% | +0.00% |
| 2023-12-31 | +57.86% | +4.04% | +24.17% | +21.34% | +13.93% | +0.00% |
| 2023-09-30 | +57.86% | +4.91% | +22.45% | +19.79% | +14.78% | +0.00% |
| 2023-06-30 | +57.86% | +2.80% | +23.38% | +20.48% | +15.96% | +0.00% |
| 2023-03-31 | +57.86% | +4.33% | +23.23% | +20.25% | +14.58% | +0.00% |
| 2022-12-31 | +57.86% | +4.67% | +23.13% | +19.49% | +14.33% | +0.00% |
| 2022-09-30 | +57.86% | +6.10% | +21.93% | +18.48% | +14.11% | +0.00% |
| 2022-06-30 | +57.87% | +0.00% | +26.77% | n/a | n/a | +0.00% |
| 2022-03-31 | +58.00% | +0.00% | +23.18% | n/a | n/a | +0.00% |
| 2021-12-31 | +58.00% | +0.00% | +22.96% | n/a | n/a | +0.00% |
| 2021-09-30 | +58.02% | +0.00% | +22.76% | n/a | n/a | +0.00% |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 456,449.49 cr | 37.677543 | +15.50% | +15.99% |
| DIVISLAB | DIVI S LABORATORIES LTD | 228,223.36 cr | 78.319614 | +18.37% | +42.62% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 165,719.79 cr | 75.983398 | +17.33% | +34.25% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 124,992.04 cr | 63.823550 | +21.03% | +9.67% |
| CIPLA | CIPLA LTD | 115,693.19 cr | 34.304976 | +10.25% | -10.08% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 112,698.21 cr | 22.474914 | +17.93% | +13.61% |
| LUPIN | LUPIN LIMITED | 100,669.80 cr | 14.727517 | +34.34% | +12.19% |
| MANKIND | MANKIND PHARMA LIMITED | 98,418.27 cr | 47.977550 | +13.18% | -8.31% |
Try these prompts
- Analyze GLAND PHARMA with valuation, momentum and industry peers
- Compare GLAND with other Healthcare stocks
- Show mid-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View mid-cap stocks
- Find stocks above 50DMA
- Compare GLAND with other Healthcare stocks
Data snapshot: 2026-08-21. Not investment advice.